Pfizer’s updated vaccine candidates, a monovalent and a bivalent option, both delivered a “substantially higher immune response” against omicron compared to its current version among study participants 56 and older when used as a fourth booster dose.
Read the full post on Becker's Hospital Review - Healthcare News
